BIOMAT Database Logo BIOMAT Database Logo

Treatment of experimental allergic myasthenia gravis with a new immunosuppressant: 15-deoxyspergualin. 1988

Y Ishigaki, and T Sato, and S Tong-Lin, and K Hayashi
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D006146 Guanidines A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Y Ishigaki, and T Sato, and S Tong-Lin, and K Hayashi
A novel immunosuppressant 15-deoxyspergualin and thrombopoiesis.
July 1994, [Hokkaido igaku zasshi] The Hokkaido journal of medical science,
Y Ishigaki, and T Sato, and S Tong-Lin, and K Hayashi
The immunosuppressant LF 15-0195 prevents experimental autoimmune myasthenia gravis in Brown-Norway rats.
November 2002, Transplantation proceedings,
Y Ishigaki, and T Sato, and S Tong-Lin, and K Hayashi
Suppression of experimental allergic encephalomyelitis by 15-deoxyspergualin.
December 1987, Journal of the neurological sciences,
Y Ishigaki, and T Sato, and S Tong-Lin, and K Hayashi
Immunosuppressant drugs for myasthenia gravis.
January 2009, Journal of neurology, neurosurgery, and psychiatry,
Y Ishigaki, and T Sato, and S Tong-Lin, and K Hayashi
Treatment of experimental myasthenia gravis with cyclosporin A.
February 1985, Clinical immunology and immunopathology,
Y Ishigaki, and T Sato, and S Tong-Lin, and K Hayashi
Effect of a new immunosuppressant, 15-deoxyspergualin, on heterotopic rat heart transplantation, in comparison with cyclosporine.
October 1987, Transplantation,
Y Ishigaki, and T Sato, and S Tong-Lin, and K Hayashi
Steroids and immunosuppressant drugs in myasthenia gravis.
June 2008, Nature clinical practice. Neurology,
Y Ishigaki, and T Sato, and S Tong-Lin, and K Hayashi
Deoxyspergualin--a novel immunosuppressant.
January 1994, The Mount Sinai journal of medicine, New York,
Y Ishigaki, and T Sato, and S Tong-Lin, and K Hayashi
Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin.
December 1995, Therapeutic drug monitoring,
Y Ishigaki, and T Sato, and S Tong-Lin, and K Hayashi
Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin.
December 1998, Biochemical and biophysical research communications,
Copied contents to your clipboard!